SABS

2.8402.41%
DS

David Scott Zaccardelli

Independent Chair of the Board

Dr. David Scott Zaccardelli, also known as Dave, Pharm.D., is Chair of the Board of SAB Biotherapeutics, Inc. from January 7, 2026. He serves as Director at Vor Biopharma Inc. since July 07, 2026. He had been President, Chief Executive Officer and Executive Director of Verona Pharma plc since February 1, 2020. Dr. Zaccardelli has been Director of Elucida Oncology, Inc. since April 2021. He served as Director of Melinta Therapeutics, Inc. until April 20, 2020. He has served as Founder and Managing Member of Bull City Select Investments, LLC since 2016. He served as President and Chief Executive Officer of Dova Pharmaceuticals Inc. from December 2018 to November 12, 2019. From December 2018 until its acquisition by Swedish Orphan Biovitrum in November 2019. Dr. Zaccardelli served as the Acting Chief Executive Officer of Cempra, Inc. from December 09, 2016 to November 2017. From 2004 until 2016, Dr. Zaccardelli served in several senior management roles at United Therapeutics Corporation Dr. Zaccardelli served as the Chief Operating Officer and Executive Vice President of United Therapeutics Corporation from January 1, 2015 to June 26, 2016. He served as the Chief Manufacturing Officer and Executive Vice President of Pharmaceutical Development at United Therapeutics Corporation from 2008 to December 31, 2014. Dr. Zaccardelli joined United Therapeutics in 2004 as Vice President of Pharmaceutical Development. Dr. Zaccardelli founded and led a startup company focused on contract pharmaceutical development services, from 1997 to 2003. From 1988 to 1996, Dr. Zaccardelli worked at Burroughs Wellcome & Co. and Glaxo Wellcome, Inc. in a variety of clinical research positions. He served as a Director at Dova Pharmaceuticals, Inc. since April 26, 2019 until November 12, 2019. He served as Director of Clinical and Scientific Affairs for Bausch & Lomb Pharmaceuticals from 1996 to 1997. Dr. Zaccardelli serves on the board of directors of Evecxia, Inc. and CoreRx, Inc., both privately held companies. Dr. Zaccardelli served as a Director of Cempra, Inc. since August 11, 2016. Dr. Zaccardelli received his Pharm.D. from the University of Michigan and completed a fellowship in clinical research and drug development at the University of North Carolina.

Positions